Odyssey Therapeutics, Inc. (ODTX) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $5.00K; Additional Paid in CapitalUSD $1.08B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-505.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $82.85M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-147.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $79.62M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $245.00K.
- 2025-06-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m).
Odyssey Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $5.00K | $1.08B | $-505.00K | $-659.19M | $421.22M | 3 month · $5.67M |
| 2026-03-31 | (m) | $0.00 | $82.85M | $-147.00K | $-606.40M | $-523.69M | 3 month · $2.59M |
| 2025-12-31 | $0.00 | $0.00 | $79.62M | $245.00K | $-568.14M | $-488.28M | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | (m) | $-436.36M | 3 month · $3.70M |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | $-417.17M | 3 month · $2.99M |
| 2024-12-31 | (m) | (m) | (m) | (m) | (m) | $-382.53M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |